Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

We are continuously upgrading the site to bring up something awesome!

Biopharma firm spins off cancer research to mine Dogecoin instead – Inside Solana



  • Coeptis will spin off its cancer therapies and pivot to Dogecoin mining.
  • The new company will operate 9,000 Dogecoin mining machines.
  • Four Dogecoin ETF applications are awaiting SEC approval.

After years of advancing cancer and autoimmune therapies, one biopharma firm is taking the next logical step: Dogecoin mining.

Coeptis Therapeutics, a publicly traded biopharmaceutical company, announced this week it would spin off its life sciences operations and merge with Z Squared, a digital asset miner focused primarily on Dogecoin.

Following the merger, the public entity will rebrand as Z Squared Inc. and focus entirely on its goal of building the largest publicly traded Dogecoin mining operation in the US.

The company’s research into cell therapies for cancer, infectious, and autoimmune diseases will continue under a separate private offshoot.

Meanwhile, Coeptis’ public shareholders will retain exposure to the newly combined Dogecoin mining business.

“We’re giving shareholders a chance to get involved in the Dogecoin market,” said Coeptis CEO Dave Mehalick, “while continuing to work on our biopharmaceutical operations through the spinout.”

Z Squared’s leadership, including incoming CEO David Halabu and COO Michelle Burke, will assume control of the newly branded company.

The deal includes 9,000 US-based Dogecoin mining machines, and the combined entity will continue trading on the Nasdaq.

Dogecoin now boasts a market cap of nearly $28 billion and has been a consistent top-10 cryptocurrency since its inception in 2013.

It operates on a proof-of-work blockchain, akin to Bitcoin’s, where miners validate transactions and are rewarded with Dogecoin.

Growing demand and a friendlier regulatory outlook in the US have also helped push cryptocurrencies like Dogecoin further into the financial mainstream.

Four Dogecoin-focused exchange-traded fund applications from Bitwise, Grayscale, 21Shares, and Osprey are awaiting approval from the US Securities and Exchange Commission.

Grayscale’s and Bitwise’s applications could receive a decision as early as mid-May, while the others could extend into late 2025.

Crypto market movers

  • Bitcoin has gained 1% over the past 24 hours and is trading at $94,575.
  • Ethereum is up 1.5% in the same period to $1,805.

What we’re reading

Kyle Baird is Inside Solana’ Weekend Editor. Got a tip? Email at kbaird@dlnews.com.

Disclosure: The views and opinions expressed here belong solely to the author and do not represent the views and opinions of insidesolana.com’ editorial.